(Q37911001)

25 August 2017

1 reference

title

Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature (English)

1 reference

25 August 2017

0 references

anti-retroviral agent

0 references

cognitive dysfunction

1 reference

Timour Al-Khindi

1

1 reference

PubMed ID

21813033

25 August 2017

Konstantine K Zakzanis

series ordinal

2

1 reference

PubMed ID

21813033

25 August 2017

Wilfred G van Gorp

series ordinal

3

1 reference

25 August 2017

4 August 2011

1 reference

Journal of the International Neuropsychological Society

25 August 2017

1 reference

25 August 2017

17

1 reference

25 August 2017

6

1 reference

25 August 2017

956-969

1 reference

25 August 2017

The medial temporal lobe

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Increased detection of serum HHV-6 DNA sequences during multiple sclerosis (MS) exacerbations and correlation with parameters of MS disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Verbal fluency component analysis in adults with HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Food combination and Alzheimer disease risk: a protective diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Toxicity of antiretroviral therapy and implications for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Statistics to tell the truth, the whole truth, and nothing but the truth Formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Brain is related to behavior (p<.05).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Influence of HAART on HIV-related CNS disease and neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

HIV, antiretroviral therapies, and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Recent progress in antiretrovirals--lessons from resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Effects of antiretroviral therapy on cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Does highly active antiretroviral therapy improve neurocognitive function? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

The prevalence and incidence of neurocognitive impairment in the HAART era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

White matter abnormalities revealed by diffusion tensor imaging in non-demented and demented HIV+ patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

A meta-analysis of the neuropsychological sequelae of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

The efficacy of psychological, educational, and behavioral treatment. Confirmation from meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

Neuropsychological functioning in a cohort of HIV infected women: importance of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

7 January 2021

Long-term effects of high-dose zidovudine treatment on neuropsychological performance in mildly symptomatic HIV-positive patients: results of a randomized, double-blind, placebo-controlled investigation

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

7 January 2021

Macrophages as a source of HIV during opportunistic infections

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

7 January 2021

Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

7 January 2021

Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

7 January 2021

Introduction to Meta-Analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

7 January 2021

Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

7 January 2021

Long-term zidovudine reduces neurocognitive deficits in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

7 January 2021

Evaluation of neuropsychological performance of HIV-infected patients with minor motor cognitive dysfunction treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

7 January 2021

Highly active antiretroviral therapy improves neurocognitive functioning

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

7 January 2021

HIV-associated cognitive impairment before and after the advent of combination therapy

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

7 January 2021

Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: A preliminary report

1 reference

https://api.crossref.org/works/10.1017%2FS1355617711000968

7 January 2021

10.1017/S1355617711000968

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21813033